
Morphic Holding Investor Relations Material
Latest events

Study Update
Morphic Holding
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Morphic Holding Inc
Access all reports
Morphic Holding Inc., a biopharmaceutical company, specializes in the discovery and development of oral small-molecule integrin therapeutics. These treatments are aimed at addressing a variety of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. A key focus of their research is on MORF-057, an α4β7 integrin inhibitor designed to modulate inflammation, currently in clinical trials for treating inflammatory bowel disease. Morphic's pipeline also explores integrin targets for other gastrointestinal indications, myelofibrosis, and solid tumors among others. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
)
Bob Iger: Disney's Visionary CEO
Bob Iger is a legend in the entertainment industry, known for his visionary leadership and as one of the most influential CEOs in Disney's history.
10 Mar 2025
Ticker symbol
MORF
Country
🇺🇸 United States